Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) and Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.
Profitability
This table compares Neumora Therapeutics and Aptevo Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neumora Therapeutics | N/A | -113.81% | -96.90% |
| Aptevo Therapeutics | N/A | -389.34% | -159.11% |
Earnings & Valuation
This table compares Neumora Therapeutics and Aptevo Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neumora Therapeutics | N/A | N/A | -$243.79 million | ($1.47) | -1.24 |
| Aptevo Therapeutics | N/A | N/A | -$24.13 million | ($98.43) | -0.01 |
Neumora Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and price targets for Neumora Therapeutics and Aptevo Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neumora Therapeutics | 3 | 2 | 5 | 0 | 2.20 |
| Aptevo Therapeutics | 1 | 1 | 0 | 1 | 2.33 |
Neumora Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 338.36%. Given Neumora Therapeutics’ higher probable upside, research analysts plainly believe Neumora Therapeutics is more favorable than Aptevo Therapeutics.
Risk & Volatility
Neumora Therapeutics has a beta of 3.12, meaning that its share price is 212% more volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.
Insider & Institutional Ownership
47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 26.8% of Neumora Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Aptevo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Neumora Therapeutics beats Aptevo Therapeutics on 8 of the 12 factors compared between the two stocks.
About Neumora Therapeutics
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
About Aptevo Therapeutics
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
